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Abstract
Background: The US Food and Drug Administration Amendments Act requires results from clinical trials of Food and Drug
Administration–approved drugs to be posted at ClinicalTrials.gov within 1 y after trial completion. We compared the timing
and completeness of results of drug trials posted at ClinicalTrials.gov and published in journals.
Methods and Findings: We searched ClinicalTrials.gov on March 27, 2012, for randomized controlled trials of drugs with
posted results. For a random sample of these trials, we searched PubMed for corresponding publications. Data were
extracted independently from ClinicalTrials.gov and from the published articles for trials with results both posted and
published. We assessed the time to first public posting or publishing of results and compared the completeness of results
posted at ClinicalTrials.gov versus published in journal articles. Completeness was defined as the reporting of all key
elements, according to three experts, for the flow of participants, efficacy results, adverse events, and serious adverse events
(e.g., for adverse events, reporting of the number of adverse events per arm, without restriction to statistically significant
differences between arms for all randomized patients or for those who received at least one treatment dose). From the
600 trials with results posted at ClinicalTrials.gov, we randomly sampled 50% (n= 297) had no corresponding published
article. For trials with both posted and published results (n= 202), the median time between primary completion date and
first results publicly posted was 19 mo (first quartile = 14, third quartile = 30 mo), and the median time between primary
completion date and journal publication was 21 mo (first quartile = 14, third quartile = 28 mo). Reporting was significantly
more complete at ClinicalTrials.gov than in the published article for the flow of participants (64% versus 48% of trials,
p,0.001), efficacy results (79% versus 69%, p= 0.02), adverse events (73% versus 45%, p,0.001), and serious adverse events
(99% versus 63%, p,0.001). The main study limitation was that we considered only the publication describing the results
for the primary outcomes.
Conclusions: Our results highlight the need to search ClinicalTrials.gov for both unpublished and published trials. Trial
results, especially serious adverse events, are more completely reported at ClinicalTrials.gov than in the published
article.
Please see later in the article for the Editors’ Summary.
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Introduction
Without accessible and usable reports, research fails to help
patients and their clinicians [1]. Over the past decades,
underreporting of trial results has been increasingly acknowledged
as one of the main causes of waste of research [2–5], contributing
to biased evidence, with serious consequences for clinical practice,
research, and, ultimately, patients [1]. This waste of research can
occur at different stages: (1) failure to publish results of some
studies, particularly those with negative results, ‘‘publication bias’’
[6–8]; (2) delay in publishing results of negative studies [9], ‘‘time-
lag bias’’ [10]; and (3) failure to publish complete results for all
prespecified outcomes, ‘‘reporting bias’’ [10–14]. Among pub-
lished studies, some results may be incompletely reported and
therefore cannot be included in a meta-analysis. This is the case,
for example, when the difference in means between treatments is
reported but not a measure of precision.
To overcome these issues, the 2007 US Food and Drug
Administration Amendments Act (FDAAA) requires that the
results from clinical trials of Food and Drug Administration–
approved drugs and devices conducted in the United States must
be made publicly available at ClinicalTrials.gov within 1 y of the
completion of the trial, whether the results are published or not
[15–18]. This US public law requires a ‘‘table of the demographic
and baseline data collected overall and for each arm of the clinical
trial to describe the patients who participated in the clinical trial …
[and] a table of values for each of the primary and secondary
outcome measures for each arm of the clinical trial, including the
results of scientifically appropriate tests of the statistical signifi-
cance of such outcome measures.’’ Researchers of other trials
registered in ClinicalTrials.gov are welcome to post trial results as
well. In our study, we aimed to compare the timing and
completeness (i.e., whether all relevant information was fully
reported) of results publicly posted at ClinicalTrials.gov and in
published articles for trials of drug interventions.
Methods
We identified trials with results posted on ClinicalTrials.gov and
their corresponding full-text publications in journals.
Search for Trials with Results Posted at ClinicalTrials.gov
We searched ClinicalTrials.gov on March 27, 2012, using the
following keywords: ‘‘Closed study’’ in the Recruitment field,
‘‘With results’’ for Study Results, ‘‘Interventional studies’’ for
Study Type, and ‘‘Phase III and IV’’ for Phase. We selected
completed phase III or IV randomized controlled trials listing only
drugs as intervention type. We excluded trials comparing a drug to
a device. We excluded phase II/III trials, considering them to be
phase II trials. Of all eligible trials (n= 1,592), we selected a
random sample of 600 trials for which to search for full-text
publications.
Search for Publication of Results in Journals
Whenever possible, we used the link within ClinicalTrials.gov to
identify the published article. We also systematically searched
MEDLINE via PubMed by using the ClinicalTrials.gov identifi-
cation number (NCT number). If no publication was identified, we
searched MEDLINE via PubMed again by using keywords for
drug names and the condition studied. The articles identified
through the search had to match the corresponding trial in terms
of the information registered at ClinicalTrials.gov (i.e., same
objective, same sample size, same primary outcome, same
location, same responsible party, same trial phase, and same
sponsor) and had to present results for the primary outcome. A
second reviewer checked the matching between ClinicalTrials.gov
and the published article. All disagreements were resolved by
discussion between the two reviewers.
In order to compare the reporting between the ClinicalTrials.
gov report and the published article, we excluded trials for which
results were published in a journal that could not be retrieved or
were published in a language other than English, French, or
Spanish. We also excluded single-arm studies because they lacked
a control group, as well as studies with four or more arms, for
practical reasons.
Data Extraction
We collected the following information from ClinicalTrials.gov
for the random sample of 600 trials with results posted at
ClinicalTrials.gov:
1. General characteristics of the trial: primary funding sources
(extracted from Study Sponsor at ClinicalTrials.gov), medical
specialty (extracted from Conditions at ClinicalTrials.gov), and
countries where the trial was conducted (extracted from
Location Countries at ClinicalTrials.gov). We also collected
trial primary completion date (defined as the date of final
collection of data for the primary outcome) and date when
results were first publicly posted—this date was extracted from
the archive record and differs from the date on which results
were first received, which is available under Study Results at
ClinicalTrials.gov. The difference between these two dates is
related to production and the vetting of the results by the US
National Institutes of Health.
2. Design of the trial: we noted whether the trial was a phase III
or IV trial. We recorded whether it was a parallel or crossover
trial.
3. Interventions: details concerning interventions for experimen-
tal and control groups were extracted from Study Arm(s) at
ClinicalTrials.gov.
Then, for all trials with both results posted and published, we
collected the following information independently from Clinical
Trials.gov and from the published article:
1. Flow of participants in the trial: reporting of the flow of
participants, including number of participants assessed for
eligibility, number of participants randomized overall and per
arm, number of participants who received the intervention per
arm and whether the reasons for not receiving the intervention
were specified, number of patients lost to follow-up and those
who discontinued the intervention and whether the reasons for
discontinuation were given, and number of participants
analyzed per arm and whether the reasons for excluding
participants from the analysis were reported.
2. Efficacy results: for the primary outcome posted at
ClinicalTrials.gov, we extracted data from ClinicalTrials.gov
for this outcome. If several primary outcomes were posted at
ClinicalTrials.gov, we focused on the first registered. When we
extracted efficacy results in the published article, we extracted
data for this outcome whether it was reported as primary or
secondary. If the outcome was not reported at all, we
considered the data to be missing. For all types of outcomes,
we collected whether numbers of patients analyzed per arm
were reported. For binary outcomes, we collected whether the
number of events per arm was reported. For continuous
outcomes, we collected whether (1) mean (6 standard deviation
[SD]) or (2) median (interquartile) was reported or (3) neither of
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these was reported. For time-to-event outcomes, we collected
whether the results of the log-rank test or Cox proportional
hazard model were reported.
3. Adverse events: we noted whether adverse events were
reported and whether they were reported by number per
arm. We collected whether all adverse events were reported or
only common events were reported or those with statistically
significant differences between arms. We noted whether
reporting of adverse events concerned all randomized partic-
ipants or only those who received at least one treatment dose.
We also collected whether withdrawals due to adverse events
were reported.
4. Serious adverse events: we collected whether serious adverse
events were reported, were reported per arm, and were
reported with numerical data.
All data were extracted in duplicate by two reviewers in data
collection forms. All disagreements were resolved by discussion to
reach a consensus, including intervention of a third reviewer in
case of discrepancies.
We also extracted the characteristics of the publication (i.e., the
journal in which the article was published, the date of online
publication, the type of journal [general medical, medical
specialty], and whether the NCT number was reported in the
published article).
Assessment of the Completeness of Reporting
Three experts in clinical epidemiology reached consensus on the
main elements that needed to be reported for each of the following
domains: the flow of participants during the trial, efficacy results,
adverse events, and serious adverse events, on the basis of data
required to perform meta-analyses. The reporting was considered
complete for each domain if all of the included elements in Box 1
were reported and incomplete if one or more elements were
missing from the items listed in Box 1.
In a second step, we compared the number of elements reported
at ClinicalTrials.gov and in the published article for the flow of
participants, efficacy results, adverse events, and serious adverse
events. We assessed the number of pairs (with percentage) for
which ClinicalTrials.gov provided more information (higher
number of elements reported), similar information (same number
of elements reported), and less information (lower number of
elements reported) as compared with the published article for the
flow of participants, efficacy results, adverse events, and serious
adverse events as defined above.
Statistical Analyses
Inter-rater agreement between the two reviewers was assessed
by the Kappa coefficient (95% CI). Descriptive analyses of trial
characteristics included numbers and percentages. Time from trial
primary completion date to the date of posting of results at
ClinicalTrials.gov or online publication in journals was described
with the Kaplan and Meier method for trials with results both
posted at ClinicalTrials.gov and published.
We compared results posted at ClinicalTrials.gov and in the
published article for completeness of reporting using McNemar’s
test of equality of paired proportions. We tested the interaction
between completeness of reporting at ClinicalTrials.gov and in the
published article and the following trial characteristics: type of
journal (general versus specialty), type of control (active versus
placebo or no treatment), source of funding (academic, industry,
both), and study design (parallel arms versus crossover) using a
generalized estimation equation (GEE) model to take into account
the correlation between the paired observations.
All tests were two-tailed, and p,0.05 was considered statistically
significant. Analyses were conducted using R version 2.15.1 [19].
Results
Figure 1 describes the selection of trials. Briefly, from the 2,837
trials retrieved by a search of ClinicalTrials.gov on March 27,
2012, we identified 1,592 completed phase III or IV randomized
drug trials with results posted at ClinicalTrials.gov. We selected a
random sample of 600 trials to search for corresponding
publications.
Time to Posting Results at ClinicalTrials.gov and
Publication in Journals
Of the 600 trials with results posted at ClinicalTrials.gov that
were randomly selected for a search for corresponding publica-
tions, we excluded five that were not randomized controlled trials,
and one that was still enrolling patients. From the remaining 594
trials, 297 (50%) had no corresponding published article. The
median year of completion of trials with no corresponding article
was 2009 (first quartile [Q1] = 2008, third quartile [Q3] = 2009).
We included 202 pairs of reports for publicly posted and published
results. In total, 18 of the 202 trials (9%) had multiple publica-
tions (from two to 14). These reports concerned protocols or
Box 1. Definition of Completeness of
Reporting
The reporting was considered complete for each domain
if all of the included elements were reported and
incomplete if one or more elements were missing:
Flow of participants
Number of patients randomized per arm and
Number of patients lost to follow-up per arm and
Number of patients analyzed per arm
Efficacy results
For binary outcomes:
Number of events per arm and
Number of patients analyzed per arm
For continuous outcomes:
MeanormedianperarmandSDorSEor95%CIorQ1–Q3or
Effect size (difference in means or standardized mean
difference) with 95% CI
For time-to-event outcomes:
Hazard ratio with 95% CI
Adverse events
Number of adverse events per arm without restriction to
statistically significant differences between arms for all
randomized participants or for those who received at least
one treatment dose
Serious adverse events
Number of serious adverse events per arm
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preliminary results such as baseline results (n= 6), interim analyses
(n= 3), long-term outcomes (n= 15), other outcomes (n= 19), and/
or other results (n= 1). None of the eliminated reports contained
additional safety data for the same time frame as the selected
report. Two of the eliminated reports contained additional safety
results for longer-term follow-up. The median time between
primary completion date and results first being publicly posted at
ClinicalTrials.gov was 19 mo (Q1 = 14, Q3 = 30 mo); the median
time between primary completion date and publication in journals
was 21 mo (Q1 = 14, Q3 = 28 mo) (Figure 2).
Characteristics of Trials with Both Posted and Published
Results
Inter-rater agreement between the 2 reviewers was good overall,
with median Kappa coefficient 0.80 (range 0.47–0.95) for
qualitative variables and 0.98 (0.91–0.99) for quantitative
variables.
For the 202 trials with both posted and published results, 69%
(139/202) were phase III trials and 31% (63/202) were phase IV
trials (Table 1). The primary source of funding was industry for
85% (173/202) of trials, academic for 10% (20/202), and both for
5% (9/202). In total, 75% (152/202) of trials had at least one site
in the United States; for 68% (138/202), results were published in
specialty medical journals, and for 32% (64/202) in general
journals. For 79% (160/202) of trials, the NCT number was
reported in the published article.
Reporting of Flow of Participants
For the 202 trials with both publicly posted and published
results, the number of patients assessed for eligibility was reported
for 1% (2/202) of trials at ClinicalTrials.gov and for 65% (131/
202) in the published article (Table 2). The number of patients
allocated to the intervention group was reported for 99% (200/
202) of trials at ClinicalTrials.gov and for 95% (192/202) in the
published article. The number of patients lost to follow-up per
group was reported for 66% (133/202) of trials at ClinicalTrials.
gov and for 53% (108/202) in the published article. The number
of patients analyzed was reported for 96% (193/202) of trials at
ClinicalTrials.gov and for 88% (177/202) in the published article.
The reasons for participant exclusion from the analysis were
reported for only 8% of trials (16/202) at ClinicalTrials.gov and
7% (14/202) of published articles.
Reporting of Efficacy Results
For trials with a binary outcome (n= 73), the number of patients
analyzed was reported for 97% (71/73) of trials at ClinicalTrials.
gov and for 89% (65/73) in the published article (Table 3). The
number of events was reported for 55% (40/73) of trials at
ClinicalTrials.gov and for 66% (48/73) in the published article. For
trials with a continuous outcome (n= 107), the mean or median
was reported for 100% (107/107) of trials at ClinicalTrials.gov
and for 90% (96/107) in the published article (Table 3). Dispersion
was reported for 96% (103/107) of trials at Clinical
Trials.gov and for 64% (69/107) in the published article. For
trials with a time-to-event outcome (n= 22), the median time to
event was reported for 50% (11/22) of trials at ClinicalTrials.gov
and for 41% (9/22) in the published article (Table 3). The number
of events was reported for 32% (7/22) of trials at ClinicalTrials.gov
and for 32% (7/22) in the published article. The hazard ratio with
95% CI was reported for 68% (15/22) of trials at ClinicalTrials.
gov and for 73% (16/22) in the published article.
The comparison of efficacy results between ClinicalTrials.gov and
the published article could not be performed in 96/202 (48%) trials:
1. For 42/73 (58%) trials with binary outcomes the comparison
could not be made because of incomplete reporting of the
number of events. This information was missing in 33 (79%)
trials at ClinicalTrials.gov, 25 (60%) in the published article,
and 16 (38%) in both data sources. For the 31 trials reporting
this information both at ClinicalTrials.gov and in the published
article, the numbers of events were the same for 27 (87%).
2. For 45/107 (42%) trials with continuous outcomes, the
comparison could not be made: nine (20%) because of different
types of analysis (e.g., the final-value mean [SD] was reported at
ClinicalTrials.gov, experimental arm, 1.12 [0.54], and control
arm, 1.14 [0.55], while the change-from-baseline mean [95% CI]
was reported in the published article, experimental arm, 0.59
[0.47 to 0.71], and control arm, 0.54 [0.41 to 0.67]), and 36 (80%)
because of incomplete or different reporting between the two
sources (e.g., different rounding used; SD reported in one source
and standard error [SE] reported in the other).
3. For 9/22 (41%) trials with time-to-event outcomes the
comparison could not be made because of incomplete
reporting of hazard ratio (95% CI). This information
was missing in seven (78%) trials at ClinicalTrials.gov, six
(67%) in the published article, and four (44%) in both data
sources.
Reporting of Adverse Events
For the 202 pairs of trial reports, the population for analysis
corresponded to all randomized participants for 57% (115/202) of
trials at ClinicalTrials.gov and 36% (72/202) of published articles
(Table 4). The total number of adverse events was reported for
96% (194/202) of trials at ClinicalTrials.gov and for 63% (128/
202) in the published article. All adverse events per arm were
reported for 13% (26/202) of trials at ClinicalTrials.gov and for
5% (10/202) in the published article. Otherwise, reporting was
restricted to the most common events for 99% (174/176) of trials
at ClinicalTrials.gov and for 44% (85/192) in the published
article, or to statistically significant events for 15% (29/192) of
trials in the published article. Withdrawals due to adverse events
were reported for 80% (161/202) of trials in ClinicalTrials.gov and
for 76% (153/202) in the published article. There was some
mention of serious adverse events for 99% (200/202) of trials at
ClinicalTrials.gov and for 71% (144/202) in the published article,
and all serious adverse events were reported per arm for 99%
(199/202) and 63% (127/202), respectively.
Completeness of Reporting
For the 202 pairs of trial reports, the proportion of trials with
complete reporting was significantly higher at ClinicalTrials.gov
than in the published article for the flow of participants (64% [129/
202] versus 48% [96/202] of trials, p,0.001), efficacy results (79%
[159/202] versus 69% [140/202], p= 0.02), adverse events (73%
[147/202] versus 45% [91/202], p,0.001), and serious adverse
events (99% [199/202] versus 63% [127/202], p,0.001) (Table 5).
We found statistically significant interactions between com-
pleteness of reporting of adverse events and type of journal (74%
and 38%, respectively, in ClinicalTrials.gov and in the published
article for trials published in a specialty journal versus 70% and
59%, respectively, for trials published in a general journal, p for
interaction = 0.015) as well as source of funding (75% and 5%,
respectively, in ClinicalTrials.gov and in the published article
for trials with academic funding; 73% and 50%, respectively, for
trials with industry funding; and 56% and 33%, respectively, for
trials with academic and industry funding, p for interaction = 0.01).
Results at ClinicalTrials.gov and in Journals
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There was more information reported at ClinicalTrials.gov than
in the published article for 29% (59/202) of trials for the flow of
participants, 21% (42/202) for efficacy results, 40% (80/202) for
adverse events, and 36% (73/202) for serious adverse events.
There was less information in ClinicalTrials.gov than in the
published article for 10% (21/202) of trials for the flow of
participants, 10% (21/202) for efficacy results, 12% (24/202) for
adverse events, and 1% (1/202) for serious adverse events of trials
(Table 6).
Discussion
To our knowledge, this is the first study comparing the timing
and completeness of trial results publicly posted at ClinicalTrials.
Figure 1. Flow diagram of selection of relevant trials. NCTs, NCT numbers.
doi:10.1371/journal.pmed.1001566.g001
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gov and published in articles. Our study is based on a random
sample of 600 drug trials with results posted at ClinicalTrials.gov
for which we searched for corresponding publications in
PubMed. For half of the trials, results were not yet published.
For trials with results both posted at ClinicalTrials.
gov and published in journals, the median time to results being
first publicly posted and published was 19 mo (Q1 = 14,
Q3 = 30 mo) and 21 mo (Q1 = 14, Q3 = 28 mo), respectively,
and the completeness of results was significantly better at
ClinicalTrials.gov than in the corresponding published articles.
In particular, serious adverse events were almost always reported
at ClinicalTrials.gov.
A previous study assessed trial publication for completed trials
registered at ClinicalTrials.gov and showed that fewer than half
were published [20]. Other studies evaluated the quality of
reporting of the World Health Organization minimum dataset in
ClinicalTrials.gov [21]. A recent study published in 2012 [22]
compared the quality of reporting among registry reports, clinical
study reports submitted to regulatory authorities, and journal
publications. The authors identified only industry registry reports,
with no trials being registered in a public registry. They
concluded that industry registry reports and journal publications
insufficiently reported the results of clinical trials but may
supplement each other. With the FDAAA requiring mandatory
posting of results within 1 y after the primary completion date
[15–17] and standardized reporting of results [17], Clinical-
Trials.gov has become an interesting source of data for assessing
trial results.
Implications
Our results have important implications for several stakehold
ers: patients and clinicians, authors, researchers performing
systematic reviews and meta-analyses, methodologists, peer
reviewers, developers of reporting guidelines, and journal editors.
For patients and their clinicians, our results outline the
importance of registries to improve transparency in clinical
research by making information about clinical trials, including
results, publicly available, which is the basis for well-informed
decision-making about patients’ health.
Our results are important for authors because they point out
inconsistencies in reporting and highlight the need for more
rigorous adherence to reporting guidelines to ensure that all
critical information is provided in study reports.
For researchers performing systematic reviews, our results
emphasize the importance of registries [23–27] in reducing
publication bias and time-lag bias. Actually, about half of the
trials with results posted at ClinicalTrials.gov did not have
published results.
Further, our results highlight the need to assess trial results
systematically from both ClinicalTrials.gov and the published
article when available. Based on our results, searching Clinical
Trials.gov is necessary for all published and unpublished trials to
obtain more complete data and to identify inconsistencies or dis-
crepancies between the publicly posted results and the publication.
As outlined by Zarin et al., ClinicalTrials.gov is designed to
complement, not replace, journal publication [28]. Nevertheless,
not all trials have their results posted at ClinicalTrials.gov. Some
Figure 2. Comparison of time from primary completion date of the trial to posting of results at ClinicalTrials.gov and to online
publication in journals for trials with both posted and published results.
doi:10.1371/journal.pmed.1001566.g002
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studies previously showed low compliance with the FDAAA
regarding mandatory posting of results at ClinicalTrials.gov [29–
32]. Moreover, this law concerns trials performed in the US, with
no similar law in Europe or elsewhere.
Our results also highlight the role of trial registries for
researchers and methodologists exploring publication bias and
selective reporting of outcomes. For example, researchers could
use trial registries to assess whether studies with a significant main
outcome are more likely to be published or published more quickly
than those with a negative outcome using data recorded in
registers.
For peer reviewers, our results emphasize the important
role of trial registration during the peer-review process.
Actually, reviewers and academic editors could assess whether
all safety events, especially serious adverse events, are fully
reported in the submitted articles. In our study, serious ad-
verse events were reported for 99% of trials at ClinicalTrials.
gov but for only 62% in the published article. A study
Table 1. Characteristics of the random sample of 600 trials with results posted at ClinicalTrials.gov for which publications were
sought.
Item Characteristic Number (Percent) of Trials with Characteristic
Sample of Trials with Results Posted
at ClinicalTrials.gov (n=600)
Sample of Trials with Results
Both Posted and Published
(n=202)
Study phase
Phase III 392 (65) 139 (69)
Phase IV 208 (35) 63 (31)
Study design
Parallel arms 550 (92) 191 (95)
Crossover 50 (8) 11 (5)
Number of arms
Two 412 (69) 158 (78)
Three 113 (19) 44 (22)
Other 75 (12) 0 (0)
Type of control treatment
Active treatment 356 (59) 105 (52)
Placebo 223 (37) 95 (47)
No treatment 21 (4) 2 (1)
Primary funding source
Industry 509 (85) 173 (85)
Academic 60 (10) 20 (10)
Academic and industry 31 (5) 9 (5)
Medical specialty
Pulmonary 58 (10) 27 (14)
Neurology 37 (7) 21 (10)
Endocrinology 65 (11) 21 (10)
Cardiology 53 (9) 20 (10)
Rheumatology 35 (6) 19 (9)
Immunology 43 (7) 18 (9)
Oncology 25 (4) 14 (7)
Others 284 (47) 62 (31)
Study location
At least one site in the US 423 (70) 152 (75)
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published in 2009 found that 73% of articles published in
journals with a high impact factor reported serious adverse
events [33]. Nevertheless, a more recent study showed that
only 34% of reviewers examined information registered in a
trial registry [34].
For developers of reporting guidelines, such as the CONSORT
group, and for editors, our study questions the current way of
reporting trials and the peer-review process. In ClinicalTrials.gov,
results are posted in a standard tabular format without discussions
or conclusions. Using templates with mandatory reporting of some
Table 2. Reporting of items concerning the flow of participants during the trial at ClinicalTrials.gov and in published articles.
Category Item
Number (Percent) of Trials
with Item Reported at
ClinicalTrials.gov (n=202)
Number (Percent) of Trials
with Item Reported in
Published Article (n=202)
Enrollment
Number of participants assessed for eligibility (overall) 2 (1) 131 (65)
Number of participants excluded (overall) 2 (1) 95 (47)
Reasons given for excluding participants 0 (0) 70 (74)
Number of participants randomized (overall) 5 (2) 181 (90)
Allocation
Number of participants allocated to intervention (per group) 200 (99) 192 (95)
Number of participants who received allocated intervention (per group) 28 (14) 80 (40)
Number of participants who did not receive allocated intervention
(per group)
10 (5) 40 (21)
Reasons given for why participants did not receive intervention (per group) 2 (20) 12 (30)
Follow-up
Number of participants lost to follow-up (per group) 133 (66) 108 (53)
Number of participants who discontinued intervention (per group) 183 (91) 140 (69)
Reported reasons for discontinuation (per group) 124 (68) 110 (79)
Analysis
Number of participants analyzed (per group) 193 (96) 177 (88)
Reported reasons for exclusion of participants from analysis (per group) 16 (8) 14 (7)
doi:10.1371/journal.pmed.1001566.t002
Table 3. Reporting of efficacy results at ClinicalTrials.gov and in published articles.
Outcome Efficacy Result Item
Number (Percent) of Trials with
Item Reported at
ClinicalTrials.gov (n=202)
Number (Percent) of Trials
with Item Reported in
Published Article (n=202)
Binary primary outcome Number of trials 73 (36) 73 (36)
Number of patients analyzed 71 (97) 65 (89)
Number of events 40 (55) 48 (66)
Continuous primary
outcome
Number of trials 107 (53) 107 (53)
Number of patients analyzed 107 (100) 91 (85)
Final value 31 (29) 24 (22)
Change from baseline 76 (71) 83 (78)
Mean or median 107 (100) 96 (90)
SD, SE, 95% CI, Q1–Q3 103 (96) 69 (64)
Effect size with 95% CI 42 (39) 47 (44)
Time-to-event primary
outcome
Number of trials 22 (11) 22 (11)
Number of patients analyzed 22 (100) 19 (86)
Number of events 7 (32) 7 (32)
Median 11 (50) 9 (41)
Hazard ratio with 95% CI 15 (68) 16 (73)
doi:10.1371/journal.pmed.1001566.t003
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elements may facilitate the work of researchers by reminding them
what they need to report and by standardizing their reporting.
Including a template for reporting the results as part of the
CONSORT guidelines could be useful to improve the complete-
ness of trials’ publication.
Furthermore, after the data results are submitted, ClinicalTrials.
gov staff members review the submissions before public posting
[18]. Data providers may be asked to clarify items or make
corrections. This systematic verification could also contribute to
the completeness of data posted. These results may help convince
publishers of the value of changes in the presentation of the results
section of articles (standardized tabular format rather than
narrative text) or of implementation of reporting guidelines. To
improve the quality of reports of clinical trials, journals—even
those endorsing the CONSORT statement—must move from
their current position of passive endorsement (for the vast majority
of them) to a more active implementation of CONSORT
guidelines [35,36].
Although the reporting of results was more complete at
ClinicalTrials.gov than in the published articles, reporting at
Table 4. Reporting of adverse events at ClinicalTrials.gov and in published articles.
Category Adverse Event Item
Number (Percent) of Trials
with Item Reported at
ClinicalTrials.gov (n=202)
Number (Percent) of Trials
with Item Reported in
Published Article (n=202)
Adverse events Population
All randomized participants 115 (57) 72 (36)
If no, patients who received at least one dose of treatment 34 (39) 57 (44)
Total number of adverse events 194 (96) 128 (63)
Reporting of adverse events
Details of all adverse events per arm 26 (13) 10 (5)
If no, restriction to most common events (e.g., occurring in $5%) 174 (99) 85 (44)
If no, restriction to statistically significant events 0 (0) 29 (15)




All randomized participants 115 (57) 72 (36)
If no, patients who received at least one dose of treatment 34 (39) 57 (44)
Reporting of serious adverse events 200 (99) 144 (71)
Details of all serious adverse events per arm 199 (99) 127 (63)
doi:10.1371/journal.pmed.1001566.t004
Table 5. Completeness of reporting for the flow of participants during the trial, efficacy results, adverse events, and serious
adverse events.

















- Number of patients randomized per arm and
- Number of patients lost to follow-up per arm and
- Number of patients analyzed per arm
129 (64) 96 (48) ,0.001
Efficacy results Reporting of:
- For binary data: number of events and analyzed patients per arm
- For continuous data: mean or median per arm and SD or SE or 95% CI or Q1–Q3 per
arm, or effect size (difference in means or standardized mean difference) with 95% CI
- For time-to-event data: hazard ratio and 95% CI
159 (79) 140 (69) 0.02
Adverse events Reporting of:
- Number of adverse events per arm, without restriction to statistically significant
differences between arms, for all randomized patients or for those who received at
least one treatment dose




- Number of serious adverse events per arm
199 (99) 127 (63) ,0.001
doi:10.1371/journal.pmed.1001566.t005
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ClinicalTrials.gov is still suboptimal and could be further
improved. Some elements, such as the number of patients assessed
for eligibility, are nearly never reported at ClinicalTrials.gov.
Other elements can be improved upon, such as the reporting of
results for binary data. At ClinicalTrials.gov, the percentage of
events rather than the number of events is frequently reported.
Both the number of events and the number of patients analyzed
per arm are needed to perform meta-analyses of binary data.
Other elements raise some important issues, including the frequent
reporting of nonserious adverse events observed in more than 5%
of patients, 5% being the default frequency threshold for reporting
nonserious adverse events at ClinicalTrials.gov according to the
FDAAA [15–17]. The reporting of adverse events observed at a
certain frequency or threshold rate has been previously outlined as
poor reporting practice [37].
Limitations
Our study has several limitations. We focused on trials with
both results posted and published. It is possible that unpublished
trial results could be published at a future date; some trials are
submitted for publication several years after completion. When
there were several publications for the same trial, we did not
include all reports resulting from the trial but only the report
describing the results for the primary outcomes. We chose this
strategy because, according to the CONSORT statement, safety
results should be reported with the main results. Only 9% of trials
had multiple publications. These reports included protocols or
preliminary or long-term results. None of the eliminated reports
contained additional safety data for the same time frame as the
selected report. Two of the eliminated reports contained
additional safety results, but for longer-term follow-up. When
assessing the completeness of reporting of efficacy results, we
focused on a single primary outcome. If several primary outcomes
were registered at ClinicalTrials.gov, we assessed the complete-
ness of reporting for only the first primary outcome registered.
Data extraction was not blinded to the source of data
(ClinicalTrials.gov or published article) because blinding would
have been impossible to achieve. Completeness of reporting was
assessed as a binary outcome (all elements reported versus not all
elements reported), so other assessment approaches may result in
different findings. Finally, we could not determine whether
publication, time to publication, and completeness were associ-
ated with risk of bias in trial design or conduct because
ClinicalTrials.gov contained insufficient methodological informa-
tion for assessing risk of bias [21,38].
Conclusions
In conclusion, our results highlight the importance of extracting
efficacy and safety data posted at ClinicalTrials.gov not only for
trials whose results are not yet published, but also for those with
published results, because we found that reporting was more
complete at ClinicalTrials.gov. Use of templates allowing for
standardized reporting of trial results in journals or broader
mandatory registration of results for all trials may help further
improve transparency.
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Editors’ Summary
Background. When patients consult a doctor, they expect
to be recommended what their doctor believes is the most
effective treatment with the fewest adverse effects. To
determine which treatment to recommend, clinicians rely on
sources that include research studies. Among studies, the
best evidence is generally agreed to come from systematic
reviews and randomized controlled clinical trials (RCTs),
studies that test the efficacy and safety of medical
interventions by comparing clinical outcomes in groups of
patients randomly chosen to receive different interventions.
Decision-making based on the best available evidence is
called evidence-based medicine. However, evidence-based
medicine can only guide clinicians if trial results are
published in a timely and complete manner. Unfortunately,
underreporting of trials is common. For example, an RCT in
which a new drug performs better than existing drugs is
more likely to be published than one in which the new drug
performs badly or has unwanted adverse effects (publication
bias). There can also be a delay in publishing the results of
negative trials (time-lag bias) or a failure to publish complete
results for all the prespecified outcomes of a trial (reporting
bias). All three types of bias threaten informed medical
decision-making and the health of patients.
Why Was This Study Done? One initiative that aims to
prevent these biases was included in the 2007 US Food and
Drug Administration Amendments Act (FDAAA). The Food
and Drug Administration (FDA) is responsible for approving
drugs and devices that are marketed in the US. The FDAAA
requires that results from clinical trials of FDA-approved
drugs and devices conducted in the United States be made
publicly available at ClinicalTrials.gov within one year of trial
completion. ClinicalTrials.gov—a web-based registry that
includes US and international clinical trials—was established
in 2000 in response to the 1997 FDA Modernization Act,
which required mandatory registration of trial titles and
designs and of the conditions and interventions under study.
The FDAAA expanded these mandatory requirements by
requiring researchers studying FDA-approved drugs and
devices to report additional information such as the baseline
characteristics of the participants in each arm of the trial and
the results of primary and secondary outcome measures
(the effects of the intervention on predefined clinical
measurements) and their statistical significance (an indi-
cation of whether differences in outcomes might have
happened by chance). Researchers of other trials registered
in ClinicalTrials.gov are welcome to post trial results as well.
Here, the researchers compare the timing and completeness
(i.e., whether all relevant information was fully reported) of
results of drug trials posted at ClinicalTrials.gov with those
published in medical journals.
What Did the Researchers Do and Find? The researchers
searched ClinicalTrials.gov for reports of completed phase III
and IV (late-stage) RCTs of drugs with posted results. For a
random sample of 600 eligible trials, they searched PubMed
(a database of biomedical publications) for corresponding
publications. Only 50% of trials with results posted at
ClinicalTrials.gov had a matching published article. For 202
trials with both posted and published results, the researchers
compared the timing and completeness of the results post-
ed at ClinicalTrials.gov and of results reported in the
corresponding journal publication. The median time be-
tween the study completion date and the first results being
publicly posted at ClinicalTrials.gov was 19 months, whereas
the time between completion and publication in a journal
was 21 months. The flow of participants through trials was
completely reported in 64% of the ClinicalTrials.gov postings
but in only 48% of the corresponding publications. Results
for the primary outcome measure were completely reported
in 79% and 69% of the ClinicalTrials.gov postings and
corresponding publications, respectively. Finally, adverse
events were completely reported in 73% of the ClinicalTrials.
gov postings but in only 45% of the corresponding
publications, and serious adverse events were reported in
99% and 63% of the ClinicalTrials.gov postings and corre-
sponding publications, respectively.
What Do These Findings Mean? These findings suggest
that the reporting of trial results is significantly more
complete at ClinicalTrials.gov than in published journal
articles reporting the main trial results. Certain aspects of
this study may affect the accuracy of this conclusion. For
example, the researchers compared the results posted at
ClinicalTrials.gov only with the results in the publication that
described the primary outcome of each trial, even though
some trials had multiple publications. Importantly, these
findings suggest that, to enable patients and physicians to
make informed treatment decisions, experts undertaking
assessments of drugs should consider seeking efficacy and
safety data posted at ClinicalTrials.gov, both for trials whose
results are not published yet and for trials whose results are
published. Moreover, they suggest that the use of templates
to guide standardized reporting of trial results in journals
and broader mandatory posting of results may help to
improve the reporting and transparency of clinical trials and,
consequently, the evidence available to inform treatment of
patients.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001566.
N Wikipedia has pages on evidence-based medicine and on
publication bias (note: Wikipedia is a free online encyclo-
pedia that anyone can edit; available in several languages)
N The US Food and Drug Administration provides informa-
tion about drug approval in the US for consumers and
health-care professionals, plus detailed information on the
2007 Food and Drug Administration Amendments Act
N ClinicalTrials.gov provides information about the US
National Institutes of Health clinical trial registry, including
background information about clinical trials, and a fact
sheet detailing the requirements of the 2007 Food and
Drug Administration Amendments Act
N PLOS Medicine recently launched a Reporting Guidelines
Collection, an open access collection of reporting guide-
lines, commentary, and related research on guidelines
from across PLOS journals that aims to help advance the
efficiency, effectiveness, and equitability of the dissemina-
tion of biomedical information; a 2008 PLOS Medicine
editorial discusses the 2007 Food and Drug Administration
Amendments Act
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